Press Releases

Press Releases

March 20, 2018 Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231

February 22, 2018 Surface Oncology Expands Board Of Directors

February 12, 2018 Surface Oncology Promotes Jeff Goater to Chief Executive Officer

June 19, 2017 Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

February 7, 2017 Surface Oncology Appoints Jeff Goater as Chief Business Officer

January 4, 2017 Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors

December 19, 2016 Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway

December 15, 2016 Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer

December 2, 2016 Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models

November 8, 2016 Surface Oncology Announces First Fully Human CD47 Antibody Entering Clinical Development in 2017

January 28, 2016 Vito Palombella, PhD Joins Surface Oncology as Chief Scientific Officer

January 11, 2016 Surface Oncology Announces Global Strategic Collaboration to Advance Next-Generation Immunotherapies

September 30, 2015 Surface Oncology named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2015  Fierce Biotech's Fierce 15

May 7, 2015 Surface Oncology Appoints Detlev Biniszkiewicz as Chief Executive Officer

January 7, 2015 Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies